O
Onkaido Therapeutics
About Onkaido Therapeutics
About Onkaido Therapeutics
Onkaido Therapeutics was established in January 2014 as a strategic venture by Moderna Therapeutics, with an initial capital commitment of $20 million. This formation represented a focused effort by Moderna to create a standalone entity dedicated exclusively to accelerating the development of messenger RNA (mRNA) based treatments for oncology. The company was headquartered in Cambridge, Massachusetts, a major hub for the biotechnology industry.
The leadership at inception included Dr. Stephen Hoge as the founding Chief Executive Officer, a role he took on in addition to his position as senior vice president at Moderna. Dr. Hoge's background includes being a partner at McKinsey & Company, where he advised leading biotech and pharmaceutical companies, and his experience was instrumental in founding Moderna's internal oncology efforts. Peter F. Smith, Ph.D., served as the founding Chief Scientific Officer, bringing 30 years of pharmaceutical leadership from companies like Millennium Pharmaceuticals, Merck, and SmithKline. His experience included contributions to the development of major drugs such as Velcade.
Onkaido's core business was to leverage Moderna's mRNA Therapeutics™ platform to address previously undruggable cancer targets. The technology is designed to use mRNA to prompt the body's own cells to produce therapeutic proteins or antibodies internally, a method intended to work with the body's natural processes. This approach was aimed at creating a new modality for cancer treatment, potentially offering a superior alternative to existing drug options. The company's initial pipeline consisted of 15 pre-clinical drug candidates focusing on areas like apoptosis, central regulatory nodes, and immunotherapy. By operating as a separate unit, Onkaido was structured to intensely focus on the specific challenges and opportunities in oncology drug development.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jan 2014 | $20M | $80M | Moderna Therapeutics | — |
Growth signals
Latest recorded traffic for Onkaido Therapeutics is 0 monthly website visits. Onkaido Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Onkaido Therapeutics in the Cambridge ecosystem
The Onkaido Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Moderna Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Onkaido Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Onkaido Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







